Astellas Pharma (FRA:YPHA) Common Stock: €561 Mil (As of Mar. 2026)


FRA:YPHA Astellas Pharma Inc FRA:YPHA
82 GF Score
Price €11.20
GF Value €11.56
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Common Stock?

Astellas Pharma FRA:YPHA +0.90% 82 Common Stock is €561 Mil as of Mar. 2026. GuruFocus rates FRA:YPHA with a GF Score™ of 82/100 and a GF Value™ of €11.56 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's quarterly common stock declined from Sep. 2025 (€594 Mil) to Dec. 2025 (€564 Mil) and declined from Dec. 2025 (€564 Mil) to Mar. 2026 (€561 Mil).

Astellas Pharma's annual common stock increased from Mar. 2024 (€633 Mil) to Mar. 2025 (€639 Mil) but then declined from Mar. 2025 (€639 Mil) to Mar. 2026 (€561 Mil).

Astellas Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Common Stock Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 788.73 719.74 632.50 639.19 561.47

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 639.19 618.08 593.50 564.17 561.47
FRA:YPHA
82GF Score
Astellas Pharma Inc FRA:YPHA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €561 Mil mean?
Astellas Pharma (FRA:YPHA) has a Common Stock of €561 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Common Stock too high?
Astellas Pharma's current Common Stock is €561 Mil. Overall, Astellas Pharma has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Common Stock compare to LLY and JNJ?
Astellas Pharma's Common Stock of €561 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Common Stock is €561 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (FRA:YPHA) is currently considered Fairly Valued. The stock's GF Value™ is €11.56, compared to a current price of €11.20 — trading 3.1% below its estimated fair value. The current Common Stock is €561 Mil. Astellas Pharma's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Astellas Pharma (FRA:YPHA), the current Common Stock is €561 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (FRA:YPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of €11.20 is trading 3.1% below its estimated GF Value™ of €11.56. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for FRA:YPHA:

  • Common Stock: €561 Mil
  • GF Value™: €11.56 vs. price of €11.20 (3.1% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the FRA:YPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score

Get the complete analysis for FRA:YPHA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.20
Price
€11.56
GF Value